{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T22:40:59Z","timestamp":1792190459071,"version":"4.4.0"},"reference-count":63,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2024,3,28]],"date-time":"2024-03-28T00:00:00Z","timestamp":1711584000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Recently, anti-programmed cell death protein 1 (PD-1)\/programmed death-ligand 1 (PD-L1) immunotherapy offers promising results for advanced biliary tract cancer (BTC). However, patients show highly heterogeneous responses to treatment, and predictive biomarkers are lacking. We performed a systematic review and meta-analysis to assess the potential of PD-L1 expression as a biomarker for treatment response and survival in patients with BTC undergoing anti-PD-1\/PD-L1 therapy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We conducted a comprehensive systematic literature search through June 2023, utilizing the PubMed, EMBASE, and Cochrane Library databases. The outcomes of interest included objective response rate (ORR), disease control rate (DCR), progression-free survival (PFS), and overall survival (OS) according to PD-L1 expression. Subgroup analyses and meta-regression were performed to identify possible sources of heterogeneity.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      A total of 30 studies was included in the final analysis. Pooled analysis showed no significant differences in ORR (odds ratio [OR], 1.56; 95% confidence intervals [CIs], 0.94-2.56) and DCR (OR, 1.84; 95% CIs, 0.88-3.82) between PD-L1 (+) and PD-L1 (-) patients. In contrast, survival analysis showed improved PFS (hazard ratio [HR], 0.54, 95% CIs, 0.41-0.71) and OS (HR, 0.58; 95% CI, 0.47-0.72) among PD-L1 (+) patients compared to PD-L1 (-) patients. Sensitivity analysis excluding retrospective studies showed no significant differences with the primary results. Furthermore, meta-regression demonstrated that drug target (PD-1\n                      <jats:italic>vs.<\/jats:italic>\n                      PD-L1), presence of additional intervention (monotherapy\n                      <jats:italic>vs.<\/jats:italic>\n                      combination therapy), and PD-L1 cut-off level (1%\n                      <jats:italic>vs.<\/jats:italic>\n                      \u22655%) significantly affected the predictive value of PD-L1 expression.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>PD-L1 expression might be a helpful biomarker for predicting PFS and OS in patients with BTC undergoing anti-PD-1\/PD-L1 therapy. The predictive value of PD-L1 expression can be significantly influenced by diagnostic or treatment variables.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Systematic review registration<\/jats:title>\n                    <jats:p>\n                      <jats:ext-link>https:\/\/www.crd.york.ac.uk\/PROSPERO<\/jats:ext-link>\n                      , identifier CRD42023434114.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fimmu.2024.1321813","type":"journal-article","created":{"date-parts":[[2024,3,28]],"date-time":"2024-03-28T00:41:28Z","timestamp":1711586488000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":21,"title":["The predictive value of PD-L1 expression in response to anti-PD-1\/PD-L1 therapy for biliary tract cancer: a systematic review and meta-analysis"],"prefix":"10.3389","volume":"15","author":[{"given":"Seung Bae","family":"Yoon","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sang Myung","family":"Woo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jung Won","family":"Chun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dong Uk","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jaihwan","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joo Kyung","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hoonsub","family":"So","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Moon Jae","family":"Chung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"In Rae","family":"Cho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Heo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2024,3,28]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2019.03.013","article-title":"Global trends in mortality from intrahepatic and extrahepatic cholangiocarcinoma","volume":"71","author":"Bertuccio","year":"2019","journal-title":"J Hepatol"},{"key":"B2","doi-asserted-by":"publisher","first-page":"17","DOI":"10.3322\/caac.21763","article-title":"Cancer statistics, 2023","volume":"73","author":"Siegel","year":"2023","journal-title":"CA Cancer J Clin"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0908721","article-title":"Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer","volume":"362","author":"Valle","year":"2010","journal-title":"N Engl J Med"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdt540","article-title":"Cisplatin and gemcitabine for advanced biliary tract cancer: a meta-analysis of two randomised trials","volume":"25","author":"Valle","year":"2014","journal-title":"Ann Oncol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1305133","article-title":"Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma","volume":"369","author":"Hamid","year":"2013","journal-title":"N Engl J Med"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1810865","article-title":"Pembrolizumab plus chemotherapy for squamous non-small-cell lung cancer","volume":"379","author":"Paz-Ares","year":"2018","journal-title":"N Engl J Med"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1510665","article-title":"Nivolumab versus everolimus in advanced renal-cell carcinoma","volume":"373","author":"Motzer","year":"2015","journal-title":"N Engl J Med"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1038\/nature13904","article-title":"MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer","volume":"515","author":"Powles","year":"2014","journal-title":"Nature"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.33013","article-title":"Efficacy and safety of pembrolizumab for the treatment of advanced biliary cancer: Results from the KEYNOTE-158 and KEYNOTE-028 studies","volume":"147","author":"Piha-Paul","year":"2020","journal-title":"Int J Cancer"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1056\/EVIDoa2200015","article-title":"Durvalumab plus gemcitabine and cisplatin in advanced biliary tract cancer","volume":"1","author":"Oh","year":"2022","journal-title":"NEJM Evidence"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(23)00727-4","article-title":"Pembrolizumab in combination with gemcitabine and cisplatin compared with gemcitabine and cisplatin alone for patients with advanced biliary tract cancer (KEYNOTE-966): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"401","author":"Kelley","year":"2023","journal-title":"Lancet"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2016.71.8023","article-title":"Overall survival in patients with advanced melanoma who received nivolumab versus investigator's choice chemotherapy in checkMate 037: A randomized, controlled, open-label phase III trial","volume":"36","author":"Larkin","year":"2018","journal-title":"J Clin Oncol"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1613493","article-title":"First-line nivolumab in stage IV or recurrent non-small-cell lung cancer","volume":"376","author":"Carbone","year":"2017","journal-title":"N Engl J Med"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2020.10.006","article-title":"The predictive value of programmed death ligand 1 in patients with metastatic renal cell carcinoma treated with immune-checkpoint inhibitors: A systematic review and meta-analysis","volume":"79","author":"Mori","year":"2021","journal-title":"Eur Urol"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.1021859","article-title":"Predictive value of PD-L1 expression in response to immune checkpoint inhibitors for esophageal cancer treatment: A systematic review and meta-analysis","volume":"12","author":"Noori","year":"2022","journal-title":"Front Oncol"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2022.3707","article-title":"Association of PD-L1 expression and other variables with benefit from immune checkpoint inhibition in advanced gastroesophageal cancer: systematic review and meta-analysis of 17 phase 3 randomized clinical trials","volume":"8","author":"Yoon","year":"2022","journal-title":"JAMA Oncol"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.5676","article-title":"The predictive value of PD-L1 expression in patients with advanced hepatocellular carcinoma treated with PD-1\/PD-L1 inhibitors: A systematic review and meta-analysis","volume":"12","author":"Yang","year":"2023","journal-title":"Cancer Med"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2020.0930","article-title":"A phase 2 multi-institutional study of nivolumab for patients with advanced refractory biliary tract cancer","volume":"6","author":"Kim","year":"2020","journal-title":"JAMA Oncol"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-158-4-201302190-00009","article-title":"Assessing bias in studies of prognostic factors","volume":"158","author":"Hayden","year":"2013","journal-title":"Ann Intern Med"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.k4597","article-title":"A guide to systematic review and meta-analysis of prognostic factor studies","volume":"364","author":"Riley","year":"2019","journal-title":"BMJ"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1016\/0197-2456(86)90046-2","article-title":"Meta-analysis in clinical trials","volume":"7","author":"DerSimonian","year":"1986","journal-title":"Control Clin Trials"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1186\/1745-6215-8-16","article-title":"Practical methods for incorporating summary time-to-event data into meta-analysis","volume":"8","author":"Tierney","year":"2007","journal-title":"Trials"},{"key":"B24","doi-asserted-by":"publisher","first-page":"1407","DOI":"10.1634\/theoncologist.2018-0044","article-title":"Ramucirumab plus pembrolizumab in patients with previously treated advanced or metastatic biliary tract cancer: nonrandomized, open-label, phase I trial (JVDF)","volume":"23","author":"Arkenau","year":"2018","journal-title":"Oncologist"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.2147\/OTT.S195537","article-title":"Efficacy and safety of nivolumab for metastatic biliary tract cancer","volume":"12","author":"Gou","year":"2019","journal-title":"Onco Targets Ther"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1016\/S2468-1253(19)30086-X","article-title":"Nivolumab alone or in combination with cisplatin plus gemcitabine in Japanese patients with unresectable or recurrent biliary tract cancer: a non-randomised, multicentre, open-label, phase 1 study","volume":"4","author":"Ueno","year":"2019","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2020-001240","article-title":"Camrelizumab plus gemcitabine and oxaliplatin (GEMOX) in patients with advanced biliary tract cancer: a single-arm, open-label, phase II trial","volume":"8","author":"Chen","year":"2020","journal-title":"J Immunother Cancer"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2019-000367","article-title":"Efficacy and biomarker analysis of nivolumab plus gemcitabine and cisplatin in patients with unresectable or metastatic biliary tract cancers: results from a phase II study","volume":"8","author":"Feng","year":"2020","journal-title":"J Immunother Cancer"},{"key":"B29","doi-asserted-by":"publisher","first-page":"594","DOI":"10.4143\/crt.2019.493","article-title":"Efficacy and safety of pembrolizumab in patients with refractory advanced biliary tract cancer: tumor proportion score as a potential biomarker for response","volume":"52","author":"Kang","year":"2020","journal-title":"Cancer Res Treat"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.21037\/hbsn-20-338","article-title":"Pembrolizumab combined with lenvatinib as non-first-line therapy in patients with refractory biliary tract carcinoma","volume":"9","author":"Lin","year":"2020","journal-title":"Hepatobiliary Surg Nutr"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2020-000564","article-title":"Phase I study of bintrafusp alfa, a bifunctional fusion protein targeting TGF-beta and PD-L1, in patients with pretreated biliary tract cancer","volume":"8","author":"Yoo","year":"2020","journal-title":"J Immunother Cancer"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.646979","article-title":"The efficacy and safety of apatinib plus camrelizumab in patients with previously treated advanced biliary tract cancer: A prospective clinical study","volume":"11","author":"Wang","year":"2021","journal-title":"Front Oncol"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.751391","article-title":"Lenvatinib plus PD-1 inhibitors as first-line treatment in patients with unresectable biliary tract cancer: A single-arm, open-label, phase II study","volume":"11","author":"Zhang","year":"2021","journal-title":"Front Oncol"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-22-1152","article-title":"Impaired chromatin remodeling predicts better survival to modified gemcitabine and S-1 plus nivolumab in advanced biliary tract cancer: A phase II T1219 study","volume":"28","author":"Chiang","year":"2022","journal-title":"Clin Cancer Res"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2021.11.012","article-title":"Regorafenib-avelumab combination in patients with biliary tract cancer (REGOMUNE): a single-arm, open-label, phase II trial","volume":"162","author":"Cousin","year":"2022","journal-title":"Eur J Cancer"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.907055","article-title":"Sintilimab combined with lenvatinib for advanced intrahepatic cholangiocarcinoma in second-line setting-A multi-center observational study","volume":"12","author":"Ding","year":"2022","journal-title":"Front Oncol"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.4593","article-title":"Tolerability and efficacy of durvalumab, either as monotherapy or in combination with tremelimumab, in patients from Asia with advanced biliary tract, esophageal, or head-and-neck cancer","volume":"11","author":"Doki","year":"2022","journal-title":"Cancer Med"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1007\/s00432-022-04166-z","article-title":"Triple therapy in biliary tract cancers: GemOX plus immune checkpoint inhibitor in combination with lenvatinib or NGS-guided targeted therapy","volume":"149","author":"Dong","year":"2023","journal-title":"J Cancer Res Clin Oncol"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1177\/17562848221117638","article-title":"Expression of PD-L1 as a predictive marker of sensitivity to immune checkpoint inhibitors in patients with advanced biliary tract cancer","volume":"15","author":"Kim","year":"2022","journal-title":"Therap Adv Gastroenterol"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1016\/j.xinn.2022.100255","article-title":"Toripalimab in advanced biliary tract cancer","volume":"3","author":"Li","year":"2022","journal-title":"Innovation (Camb)"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1016\/S2468-1253(22)00043-7","article-title":"Gemcitabine and cisplatin plus durvalumab with or without tremelimumab in chemotherapy-naive patients with advanced biliary tract cancer: an open-label, single-centre, phase 2 study","volume":"7","author":"Oh","year":"2022","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.946861","article-title":"Lenvatinib plus programmed cell death protein-1 inhibitor beyond first-line systemic therapy in refractory advanced biliary tract cancer: A real-world retrospective study in China","volume":"13","author":"Shi","year":"2022","journal-title":"Front Immunol"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.1006075","article-title":"PD-1 inhibitors plus nab-paclitaxel-containing chemotherapy for advanced gallbladder cancer in a second-line setting: A retrospective analysis of a case series","volume":"12","author":"Tan","year":"2022","journal-title":"Front Oncol"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-021-03121-0","article-title":"A real-world study of the efficacy and safety of anti-PD-1 antibodies plus lenvatinib in patients with advanced gallbladder cancer","volume":"71","author":"Zuo","year":"2022","journal-title":"Cancer Immunol Immunother"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1177\/17562848231170484","article-title":"The efficacy of immune checkpoint inhibitors in biliary tract cancer with KRAS mutation","volume":"16","author":"Jeong","year":"2023","journal-title":"Therap Adv Gastroenterol"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.34372","article-title":"Feasibility and tolerability of sintilimab plus anlotinib as the second-line therapy for patients with advanced biliary tract cancers: An open-label, single-arm, phase II clinical trial","volume":"152","author":"Jin","year":"2023","journal-title":"Int J Cancer"},{"key":"B47","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1038\/s41392-023-01317-7","article-title":"Toripalimab combined with lenvatinib and GEMOX is a promising regimen as first-line treatment for advanced intrahepatic cholangiocarcinoma: a single-center, single-arm, phase 2 study","volume":"8","author":"Shi","year":"2023","journal-title":"Signal Transduct Target Ther"},{"key":"B48","doi-asserted-by":"crossref","DOI":"10.1007\/978-3-031-22802-5","article-title":"Local-regional therapy combined with toripalimab and lenvatinib in patients with advanced biliary tract cancer","volume":"13","author":"Wang","year":"2023","journal-title":"Am J Cancer Res"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1097\/hep.0000000000000365","article-title":"Phase 2 trial of bintrafusp alfa as second-line therapy for patients with locally advanced\/metastatic biliary tract cancers","volume":"78","author":"Yoo","year":"2023","journal-title":"Hepatology"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-023-03466-8","article-title":"Efficacy, safety, and prognostic factors of PD-1 inhibitors combined with lenvatinib and Gemox chemotherapy as first-line treatment in advanced intrahepatic cholangiocarcinoma: a multicenter real-world study","volume":"72","author":"Zhu","year":"2023","journal-title":"Cancer Immunol Immunother"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1109292","article-title":"Efficacy and safety of lenvatinib combined with PD-1\/PD-L1 inhibitors plus Gemox chemotherapy in advanced biliary tract cancer","volume":"14","author":"Zhu","year":"2023","journal-title":"Front Immunol"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.18632\/aging.102588","article-title":"Prognostic role of programmed death-ligand 1 expression in patients with biliary tract cancer: a meta-analysis","volume":"11","author":"Lei","year":"2019","journal-title":"Aging (Albany NY)"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.21037\/jgo.2019.08.08","article-title":"Patterns and genomic correlates of PD-L1 expression in patients with biliary tract cancers","volume":"10","author":"Mody","year":"2019","journal-title":"J Gastrointest Oncol"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1159\/000514404","article-title":"Programmed death ligand 1 expression as a prognostic marker in patients with advanced biliary tract cancer","volume":"99","author":"Kim","year":"2021","journal-title":"Oncology"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2020.106214","article-title":"Predictive effect of PD-L1 expression for immune checkpoint inhibitor (PD-1\/PD-L1 inhibitors) treatment for non-small cell lung cancer: A meta-analysis","volume":"80","author":"Zhang","year":"2020","journal-title":"Int Immunopharmacol"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1060308","article-title":"PD-L1 expression as biomarker of efficacy of PD-1\/PD-L1 checkpoint inhibitors in metastatic triple negative breast cancer: A systematic review and meta-analysis","volume":"14","author":"Khan","year":"2023","journal-title":"Front Immunol"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.1155\/2020\/8375348","article-title":"Predictive and prognostic role of PD-L1 in urothelial carcinoma patients with anti-PD-1\/PD-L1 therapy: A systematic review and meta-analysis","volume":"2020","author":"Liu","year":"2020","journal-title":"Dis Markers"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.801909","article-title":"Efficacy and safety of anti-PD1\/PDL1 in advanced biliary tract cancer: A systematic review and meta-analysis","volume":"13","author":"Jiang","year":"2022","journal-title":"Front Immunol"},{"key":"B59","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1038\/s41379-019-0327-4","article-title":"\"Interchangeability\" of PD-L1 immunohistochemistry assays: a meta-analysis of diagnostic accuracy","volume":"33","author":"Torlakovic","year":"2020","journal-title":"Mod Pathol"},{"key":"B60","doi-asserted-by":"publisher","first-page":"12348","DOI":"10.1038\/s41598-020-69366-4","article-title":"High PD-L1 expression is associated with therapeutic response to pembrolizumab in patients with advanced biliary tract cancer","volume":"10","author":"Ahn","year":"2020","journal-title":"Sci Rep"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.3390\/curroncol28060437","article-title":"The challenge to the pathologist of PD-L1 expression in tumor cells of non-small-cell lung cancer\u2014An overview","volume":"28","author":"J\u00f6hrens","year":"2021","journal-title":"Curr Oncol"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.1038\/s41416-018-0199-2","article-title":"Mismatch repair deficiency is a rare but putative therapeutically relevant finding in non-liver fluke associated cholangiocarcinoma","volume":"120","author":"Goeppert","year":"2019","journal-title":"Br J Cancer"},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.1002\/JLB.5MA1220-631R","article-title":"Blood tests predict the therapeutic prognosis of anti-PD-1 in advanced biliary tract cancer","volume":"110","author":"Du","year":"2021","journal-title":"J Leukoc Biol"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2024.1321813\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,3,28]],"date-time":"2024-03-28T00:41:34Z","timestamp":1711586494000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2024.1321813\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3,28]]},"references-count":63,"alternative-id":["10.3389\/fimmu.2024.1321813"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2024.1321813","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,3,28]]},"article-number":"1321813"}}